JP2006502110A - 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用 - Google Patents

非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用 Download PDF

Info

Publication number
JP2006502110A
JP2006502110A JP2004519814A JP2004519814A JP2006502110A JP 2006502110 A JP2006502110 A JP 2006502110A JP 2004519814 A JP2004519814 A JP 2004519814A JP 2004519814 A JP2004519814 A JP 2004519814A JP 2006502110 A JP2006502110 A JP 2006502110A
Authority
JP
Japan
Prior art keywords
antibody
muc16
muc1
antigen
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004519814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502110A5 (https=
Inventor
ペイン，ジリアン
チッテンデン，トーマス
ゴールドマクハー，ヴィクター
チュン，フィリップ
スナイダー−マルレディ，クリスティン
ヴェイター，キャロル・エイ
Original Assignee
イミュノジェン・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノジェン・インコーポレーテッド filed Critical イミュノジェン・インコーポレーテッド
Publication of JP2006502110A publication Critical patent/JP2006502110A/ja
Publication of JP2006502110A5 publication Critical patent/JP2006502110A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004519814A 2002-07-03 2003-07-03 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用 Pending JP2006502110A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39309402P 2002-07-03 2002-07-03
PCT/US2003/020907 WO2004005470A2 (en) 2002-07-03 2003-07-03 Antibodies to non-shed muc1 and muc16, and uses thereof

Publications (2)

Publication Number Publication Date
JP2006502110A true JP2006502110A (ja) 2006-01-19
JP2006502110A5 JP2006502110A5 (https=) 2006-06-29

Family

ID=30115541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004519814A Pending JP2006502110A (ja) 2002-07-03 2003-07-03 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用

Country Status (6)

Country Link
US (1) US7202346B2 (https=)
EP (1) EP1536814A4 (https=)
JP (1) JP2006502110A (https=)
AU (1) AU2003247762B2 (https=)
CA (1) CA2491017A1 (https=)
WO (1) WO2004005470A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533061A (ja) * 2006-04-14 2009-09-17 セルセンス， インコーポレイテッド 細胞の標識を評価する方法
JP2013529061A (ja) * 2010-03-26 2013-07-18 メモリアル スローン−ケタリング キャンサー センター Ｍｕｃ１６に対する抗体およびその使用方法
JP2017505625A (ja) * 2014-01-29 2017-02-23 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体
JP2018070640A (ja) * 2012-08-14 2018-05-10 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞増強治療法
US11066480B2 (en) 2015-03-17 2021-07-20 Memorial Sloan Kettering Cancer Center Anti-MUC16 antibodies and uses thereof
JP2022109230A (ja) * 2021-01-14 2022-07-27 出光興産株式会社 ペプチドタグおよびそれを含むタグ付加タンパク質

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP2322929B1 (en) 2000-11-27 2016-04-06 Minerva Biotechnologies Corporation diagnostics, drug screening and treatment for cancer
SI2301965T1 (sl) 2002-10-16 2015-07-31 Purdue Pharma L.P. Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
CA2537263C (en) * 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
KR20120064120A (ko) * 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
CA2595778A1 (en) 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. Anti-muc1 .alpha..beta. antibodies
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ563370A (en) 2005-06-20 2010-10-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
US8252740B2 (en) * 2006-01-27 2012-08-28 The University Of Mississippi Medical Center Thermally-targeted delivery of medicaments including doxorubicin
EP2155248B1 (en) * 2007-04-12 2015-06-10 The Brigham and Women's Hospital, Inc. Targeting abcb5 for cancer therapy
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
NZ602675A (en) 2008-03-18 2014-03-28 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EP3978928A1 (en) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
AU2014271278B2 (en) * 2010-03-26 2017-01-19 Memorial Sloan-Kettering Cancer Center Antibodies to MUC16 and methods of use thereof
WO2011133555A2 (en) 2010-04-20 2011-10-27 The Research Foundation Of State University Of New York Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
US9433686B2 (en) 2011-01-31 2016-09-06 The Regents Of The University Of California Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
GB201213858D0 (en) * 2012-08-03 2012-09-19 Mab Design Ltd Method
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
CN106414726A (zh) * 2014-04-07 2017-02-15 米纳瓦生物技术公司 抗nme抗体
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2016149485A1 (en) 2015-03-17 2016-09-22 The Regents Of The University Of California Novel chemoimmunotherapy for epithelial cancer
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
WO2017096247A1 (en) 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
CN105950647A (zh) * 2016-05-16 2016-09-21 浙江理工大学 一种高效表达与制备外分泌型人源ca125的方法
WO2018009811A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
US10617773B2 (en) 2016-08-05 2020-04-14 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US11319380B2 (en) 2018-06-04 2022-05-03 Precigen, Inc. MUC16 specific chimeric antigen receptors and uses thereof
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
CN116367857A (zh) 2020-06-08 2023-06-30 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
KR20230028796A (ko) 2020-06-26 2023-03-02 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
ES2149768T3 (es) * 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
IL110464A0 (en) * 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
US20020119158A1 (en) * 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
ES2276708T3 (es) * 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
US20040146862A1 (en) * 2000-03-15 2004-07-29 Eos Biotechnology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
AU9263101A (en) * 2000-09-11 2002-03-26 Donald W Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
EP1578345A2 (en) * 2001-03-29 2005-09-28 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Peptides and antibodies to muc 1 proteins
WO2003089451A2 (en) * 2002-04-22 2003-10-30 Dyax Corporation Antibodies specific for mucin polypeptide
SI2301965T1 (sl) * 2002-10-16 2015-07-31 Purdue Pharma L.P. Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533061A (ja) * 2006-04-14 2009-09-17 セルセンス， インコーポレイテッド 細胞の標識を評価する方法
US9790283B2 (en) 2010-03-26 2017-10-17 Memorial Sloan Kettering Cancer Center Antibodies to MUC16 and methods of use thereof
JP2018117634A (ja) * 2010-03-26 2018-08-02 メモリアル スローン ケタリング キャンサー センター Ｍｕｃ１６に対する抗体およびその使用方法
US9169328B2 (en) 2010-03-26 2015-10-27 Memorial Sloan Kettering Cancer Center Antibodies to MUC16 and methods of use thereof
JP2016144468A (ja) * 2010-03-26 2016-08-12 メモリアル スローン−ケタリング キャンサー センター Ｍｕｃ１６に対する抗体およびその使用方法
JP2024073610A (ja) * 2010-03-26 2024-05-29 メモリアル スローン ケタリング キャンサー センター Ｍｕｃ１６に対する抗体およびその使用方法
JP2022088649A (ja) * 2010-03-26 2022-06-14 メモリアル スローン ケタリング キャンサー センター Ｍｕｃ１６に対する抗体およびその使用方法
JP7100595B2 (ja) 2010-03-26 2022-07-13 メモリアル スローン ケタリング キャンサー センター Ｍｕｃ１６に対する抗体およびその使用方法
JP2015025006A (ja) * 2010-03-26 2015-02-05 メモリアル スローン−ケタリング キャンサー センター Ｍｕｃ１６に対する抗体およびその使用方法
JP2019116474A (ja) * 2010-03-26 2019-07-18 メモリアル スローン ケタリング キャンサー センター Ｍｕｃ１６に対する抗体およびその使用方法
JP2020072681A (ja) * 2010-03-26 2020-05-14 メモリアル スローン ケタリング キャンサー センター Ｍｕｃ１６に対する抗体およびその使用方法
US10759869B2 (en) 2010-03-26 2020-09-01 Memorial Sloan Kettering Cancer Center Antibodies to MUC16 and methods of use thereof
JP2013529061A (ja) * 2010-03-26 2013-07-18 メモリアル スローン−ケタリング キャンサー センター Ｍｕｃ１６に対する抗体およびその使用方法
US11834513B2 (en) 2010-03-26 2023-12-05 Memorial Sloan Kettering Cancer Center Antibodies to MUC16 and methods of use thereof
JP2018070640A (ja) * 2012-08-14 2018-05-10 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞増強治療法
JP2021100942A (ja) * 2014-01-29 2021-07-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体
US11136410B2 (en) 2014-01-29 2021-10-05 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
JP7117410B2 (ja) 2014-01-29 2022-08-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１－ｃ／細胞外ドメイン（ｍｕｃ１－ｃ／ｅｃｄ）に対する抗体
JP2017505625A (ja) * 2014-01-29 2017-02-23 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体
US12466895B2 (en) 2014-01-29 2025-11-11 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-c/extracellular domain (MUC1-C/ECD)
US11066480B2 (en) 2015-03-17 2021-07-20 Memorial Sloan Kettering Cancer Center Anti-MUC16 antibodies and uses thereof
US12466894B2 (en) 2015-03-17 2025-11-11 Memorial Sloan Kettering Cancer Center Anti-MUC16 antibodies and uses thereof
JP2022109230A (ja) * 2021-01-14 2022-07-27 出光興産株式会社 ペプチドタグおよびそれを含むタグ付加タンパク質
JP7768775B2 (ja) 2021-01-14 2025-11-12 出光興産株式会社 ペプチドタグおよびそれを含むタグ付加タンパク質

Also Published As

Publication number Publication date
WO2004005470A2 (en) 2004-01-15
EP1536814A4 (en) 2006-02-15
US7202346B2 (en) 2007-04-10
EP1536814A2 (en) 2005-06-08
WO2004005470A3 (en) 2004-04-29
US20040057952A1 (en) 2004-03-25
CA2491017A1 (en) 2004-01-15
AU2003247762A1 (en) 2004-01-23
AU2003247762B2 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
US7202346B2 (en) Antibodies to non-shed Muc1 and Muc16, and uses thereof
RU2758113C2 (ru) Антитела к muc16 и их применение
EP2104513B1 (en) Ovr110 antibody compositions and methods of use
JP4898120B2 (ja) Ｇｐｒ６４に対する抗体とその利用法
CN103073641B (zh) 在体内具有抗肿瘤活性的抗人Dlk-1抗体
JP5028635B2 (ja) Ｆｚｄ１０に対する腫瘍標的化モノクローナル抗体とその使用
JP5601836B2 (ja) Ｔｅｓ７およびｔｅｓ７に結合する抗体
JP5903717B2 (ja) ヒト抗ミュラーホルモンｉｉ型レセプタ（ａｍｈｒ−ｉｉ）に対するモノクローナル抗体とそのフラグメント
US20210269549A1 (en) Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
CN101142236B (zh) Adam-9调节剂
US20030096285A1 (en) Identifying anti-tumor targets or agents by lipid raft immunization and proteomics
US20110206657A1 (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
JP7122361B2 (ja) 抗Ａｇｇｒｕｓモノクローナル抗体、ＣＬＥＣ－２との結合に必要なＡｇｇｒｕｓの領域、及びＡｇｇｒｕｓ－ＣＬＥＣ‐２結合阻害剤のスクリーニング方法
RU2768002C1 (ru) Антитело, специфически связывающееся с ecl-2 клаудина 3, его фрагмент и его применение
JP5847755B2 (ja) 細胞を検出する方法、およびこれに有用な薬剤
JP2017505107A (ja) Ｃｃｒ９に対する抗体およびその用途
CN1662254A (zh) Alcam和alcam调制剂
CN101547936A (zh) 癌性疾病调节抗体
WO2021251459A1 (ja) ヒト化抗ｇｐｃ－１抗体
RU2816850C2 (ru) Антитела для лечения раковых заболеваний, при которых экспрессируется клаудин 6

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091019